BCL2 and diffuse large B-cell lymphoma: Further, the differential recovery from alisertib observed between U2932 and VAL indicate MYC/BCL2 translocated (DH) have a more aggressive phenotype compared with MYC/BCL2 over-expressed (DE) DLBCL, the former with a worse prognosis [21].